Keywords: Teva, :aquinimod, Novartis, Gilenya, Multiple sclerosis, Nomura, MS
Laquinimod’s modest efficacy means it is no threat to Novartis’ Gilenya in MS, says Nomura
Article | 02 August 2011
Commenting on the failure of Teva Pharmaceutical Industries’ (Nasdaq: TEVA) Phase III trial for multiple sclerosis drug candidate laquinimod ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
